The difference of ARB101 positive CTCs between those 2 groups of matched patient samples are statistically significant (p < 0.0001). CTC detection by ARB101 antibody could serve as a potential non-invasive approach for CRC detection, progression, and monitoring treatment response of colorectal cancers.